Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27767349 | 0.95 | PDK2 (0.36) | CHRM2CHRM1CHRM3PDK2BACE1 | |
| SCHEMBL2878160 | 0.84 | PDK2 (0.37) | PDK2CYP2C9CYP2C19RECQLKMT2A | |
| SCHEMBL22703883 | 0.79 | GPR3 (0.36) | PDK2SIGMAR1NR5A2 | |
| SCHEMBL24614623 | 0.79 | TSHR (0.37) | PDK2CYP2C19L3MBTL1 | |
| SCHEMBL27789054 | 0.79 | PDK2 (0.36) | PDK2CYP2C19KMT2A | |
| SCHEMBL4123928 | 0.76 | PDK2 (0.32) | PDK2 | |
| SCHEMBL12692197 | 0.76 | PDK2 (0.32) | PDK2 | |
| SCHEMBL3978361 | 0.75 | ALDH1A1 (0.44) | PDK2CYP2C9CYP2C19RECQLNPSR1 | |
| SCHEMBL4114564 | 0.75 | PDK2 (0.39) | PDK2CYP2C9CYP2C19MEN1RECQL | |
| SCHEMBL4108492 | 0.72 | PDK2 (0.36) | PDK2CYP2C9CYP2C19RECQLNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057174-B1 | NEW CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-12-17 | — | — | EP | claimed |
| US-8618328-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| US-20120245348-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and their Use in Catalytic Reactions | PLENIO HERBERT (DE) | 2012-09-27 | — | — | US | claimed |
| US-20090253907-A1 | CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2009-10-08 | — | — | US | claimed |
| EP-1894938-A1 | New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | Evonik Degussa GmbH (DE) | 2008-03-05 | — | — | EP | claimed |
| US-8969624-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2057174-B1 | NEW CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20140058101-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and Their Use in Catalytic Reactions | EVONIK DEGUSSA GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-8618328-B2 | Cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | EVONIK DEGUSSA GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20120245348-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and their Use in Catalytic Reactions | PLENIO HERBERT (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20120245348-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and their Use in Catalytic Reactions | PLENIO HERBERT (DE) | 2012-09-27 | — | — | US | disclosed |
| US-20090253907-A1 | CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253907-A1 | CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | EVONIK DEGUSSA GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-1894938-A1 | New cyclopentadienyl, indenyl or fluorenyl substituted phosphine compounds and their use in catalytic reactions | Evonik Degussa GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245348-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and their Use in Catalytic Reactions | PHOSPHO1, PPP4C, INPP5B | CHRM2 3466/4885CHRM1 2402/4885CHRM3 2523/4885 |
| US-20140058101-A1 | New Cyclopentadienyl, Indenyl or Fluorenyl Substituted Phosphine Compounds and Their Use in Catalytic Reactions | CPS1, CYCS, PFAS | CHRM2 3077/4885CHRM1 1715/4885CHRM3 2846/4885 |
| US-20090253907-A1 | CYCLOPENTADIENYL, INDENYL OR FLUORENYL SUBSTITUTED PHOSPHINE COMPOUNDS AND THEIR USE IN CATALYTIC REACTIONS | CPS1, CYCS, RRS1 | CHRM2 3612/4885CHRM1 1829/4885CHRM3 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.